GLP-1 TV · News & media
🚨🚨🚨BREAKING NEWS ON: #Retatrutide from #EliLilly makers of #Mounjaro
Today’s cheapest tirzepatide$69/mo at Wellmedr, sale price.Compare all tirzepatide prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
In this short video from the On The Pen channel, the host, who gives his name as the speaker, reacts to newly released clinical trial data on retatrutide from Eli Lilly. He describes it as a triple agonist that acts on the GLP-1 receptor, the GIP receptor (as Mounjaro does) and the glucagon receptor, and says the glucagon action is what helped drive the weight loss. He notes that retatrutide is being studied for an obesity indication.
Published by On The Penâ„¢ GLP-1 News on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
Walking through slides, he says the 48 week study found the drug was well tolerated and produced meaningful weight loss. People on the highest dose, 12 milligrams, lost 24.2 percent of their body weight on average. He says everyone taking 8 milligrams or more lost at least 5 percent of their weight, and nearly half lost at least 25 percent. He also reports an average 40 percent drop in triglycerides and a 22 percent drop in LDL cholesterol, and notes that the A1C reduction was only about 0.5 percent, smaller than with Mounjaro.
The speaker compares the 48 week timeline with the 72 week Mounjaro trials and says retatrutide reached greater weight loss in less time. He also points to a chart of results by dose over time, showing large weight loss by week 24, and to reductions in liver fat among people with non-alcoholic fatty liver disease on the higher doses. He says he expects an obesity indication and market arrival by the end of next year, which is his own prediction.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:30 The speaker describes retatrutide as a triple agonist that adds the glucagon receptor to the GLP-1 and GIP targets of Mounjaro.
- 1:30 He reports that people on the 12 milligram dose lost 24.2 percent of their body weight on average over 48 weeks.
- 2:00 He says everyone on at least 8 milligrams lost at least 5 percent of their weight, and nearly half lost at least 25 percent.
- 2:30 He compares the 48 week retatrutide study with the 72 week Mounjaro trials and says retatrutide produced greater weight loss in less time.
- 3:00 He cites a 40 percent triglyceride reduction, a 22 percent LDL reduction and an A1C drop of only 0.5 percent.
- 4:03 He notes significant liver fat reductions at higher doses in people with non-alcoholic fatty liver disease, and predicts an obesity indication by the end of next year.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Mounjaro and retatrutide
Questions this video answers
How much weight did people lose on retatrutide in the 48 week trial?
According to the video, people on the highest dose, 12 milligrams, lost 24.2 percent of their body weight on average over 48 weeks. The host says nearly half of participants lost at least 25 percent.
How does retatrutide differ from Mounjaro?
The host explains that retatrutide is a triple agonist, adding the glucagon receptor to the GLP-1 and GIP targets that Mounjaro uses. He says it lowered A1C less than Mounjaro but produced more weight loss.
Did retatrutide improve cholesterol or fatty liver in the trial?
The host reports an average 40 percent reduction in triglycerides and a 22 percent reduction in LDL cholesterol. He also says higher doses significantly reduced liver fat in people with non-alcoholic fatty liver disease.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Retatrutide Explained: The Triple-Agonist After Ozempic and MounjaroAccording to the video, retatrutide is an investigational once-weekly injection from Lilly, built as a single molecule that activates the GIP, GLP-1 and glucagon receptors.- What tirzepatide costs at every program we trackToday’s lowest is $69/mo. Every program ranked by price alone. Compounded drugs are not FDA-approved.
Retatrutide Isn't a Weight Loss Drug — Here's What It Really Does (Weightloss Dr. Explains)The speaker, who says he specializes in obesity medicine and peptide therapy, argues that retatrutide should not be judged only by weight loss.
New data released on weight loss drug retatrutideThis segment features the show's chief medical correspondent, who discusses retatrutide, an experimental weight loss medication still in clinical trials.
Retatrutide, Too Good to Be True? A Dietitian Explains this new GLP-1In this video, the speaker, a registered dietitian who says she also uses a GLP-1 medication, discusses retatrutide, an experimental drug from Eli Lilly.
What Is Retatrutide? The Triple-Hormone Drug Beating OzempicIn this video, the channel explains what retatrutide is and what he says the evidence shows.
Retatrutide enters phase 3 clinical trials, what does that mean?According to the video, the host uses this episode to explain how clinical trial phases work and where Eli Lilly's upcoming weight loss drugs sit within them.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- GLP-1 vs GLP-2 vs GLP-3: what the names mean, and which ones you can actually buy
GLP-1 drugs such as semaglutide act on one receptor. "GLP-2" is used online for tirzepatide (Zepbound, Mounjaro), which acts on two, GIP and GLP-1, and "GLP-3" for retatrutide, which adds the glucagon receptor. Neither nickname is the real name: GLP-2 is a separate gut hormone whose drug, Gattex, treats short bowel syndrome. Retatrutide produced 28.3% mean weight loss at 80 weeks in its phase 3 trial but is not FDA-approved; Lilly plans to file in Q1 2027. Tirzepatide is the strongest option you can buy today.
- Retatrutide: FDA status, trial results and when it could be approved
Retatrutide is not FDA-approved: Eli Lilly plans to submit it in Q1 2027, and FDA says it cannot be compounded. The weekly triple agonist (GIP, GLP-1 and glucagon) produced 28.3% weight loss at 80 weeks in TRIUMPH-1 on Lilly's efficacy measure (25.0% counting everyone randomized), and in October 2026 it beat Ozempic 2 mg head to head. Online "research" vials are illegal. Tirzepatide is the closest legal option, compounded from $69 a month on our board.
- Mounjaro for weight loss, and why Zepbound exists
Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.
Next steps
Mounjaro prices
Find more like it
Dose changeThe trials
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















